Other highlights in JNCI, June 12

e is 12 to 15 months. Researchers hope that identifying the genes that control the progression of the disease will help them develop new therapies.

Samuel Ng, Ph.D., of the University of Hong Kong and colleagues analyzed the gene expression of CCRK in human glioma cell lines, in samples from glioma patients and normal brain tissue, and in mouse models.

They found that the overexpression of the CCRK gene was associated with a greater risk of developing glioma and increased tumor growth, whereas suppression of the gene was associated with the inhibition of tumor growth.

Our results support the rationale for developing CCRK as a potential therapeutic and diagnostic target for glioblastoma multiforme, and, possibly, other cancers, the authors write.

Contact: Marie Lin, University of Hong Kong, +852-22990776, mcllin@hkusua.hku.hk

Antitumor Compound Blocks Heat Shock Protein

Deguelin, a natural compound known to have antitumor properties, appears to disrupt the function of heat shock protein 90 (Hsp90), which cancer cells may need to grow.

Heat shock proteins are expressed in response to higher temperatures and help prevent disruptions in protein folding. Hsp90, in particular, is often overexpressed in cancer cells and maintains stability and function of several oncoproteins, known as client proteins.

Seung Hyun Oh, Ph.D., D.V.M., of the University of Texas M. D. Anderson Cancer Center in Houston, and colleagues investigated whether deguelin inhibits the function of Hsp90. Mice with transplanted human nonsmall-cell lung cancer, head and neck cancer, stomach cancer, or prostate cancer were treated with deguelin or placebo twice a day for 15-28 days.

The researchers showed that deguelin directly binds to Hsp90 and inhibits its functional activity, which results in a reduction in the expression of its client proteins. Ad

Contact: Liz Savage
Journal of the National Cancer Institute

Page: 1 2 3

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights from the June 6 JNCI
6. Other highlights in the May 16 JNCI
7. Other highlights from the April 18 Journal of the National Cancer Institute
8. Other highlights from the March 21 JNCI
9. Other highlights in the March 7 JNCI
10. Other highlights in the Feb. 21 JNCI
11. Other highlights in the Jan. 17 JNCI

Post Your Comments:

(Date:3/20/2020)... ... March 20, 2020 , ... ImStem Biotechnology, Inc. (Farmington CT), ... mesenchymal stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage ... orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
(Date:3/13/2020)... ... March 13, 2020 , ... Cryo-Cell ... stored cord blood performed by Dr. Hal Boxmeyer and colleagues, which determined sample ... cryogenically preserved cells under proper conditions. Cryo-Cell International marks the first family cord ...
(Date:3/11/2020)... ... March 11, 2020 , ... USARAD Holdings Inc., the ... and several healthcare VC firms introduces a first of its kind COVID-19 screening ... and has caused over 4,000 fatalities to date. Over the years, USARAD through ...
Breaking Biology News(10 mins):
(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... ... was invited to present the latest breast implant technology at the IMCAS Innovation ... and new innovations in the dermatology, plastic surgery, and aesthetic science industries that ...
(Date:2/28/2020)... SAN DIEGO (PRWEB) , ... February 26, 2020 ... ... HS7 system combines a high-speed camera with a dedicated controller, thus ... 2500 frames per second, the HS7 is the first of Fastec Imaging’s new ...
(Date:2/21/2020)... (PRWEB) , ... February 20, 2020 , ... In a ... join guest speakers from Synteract including Lisa Dilworth, BS, MS, Vice President ... about these challenges, with feasible strategies and solutions to support patients, sites and sponsors. ...
(Date:2/21/2020)... ... February 20, 2020 , ... The dietary supplement industry ... that what’s listed on an ingredient panel is actually in their product. ... with the adoption of CertainT, which is designed to protect the intellectual property ...
Breaking Biology Technology:
Cached News: